Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and Diet

NCT05978206 | Recruiting Phase 2

• 1 other identifier: NIGRIR_002SARKOPENIA
• Study Type: interventional
• Target: 168
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center, prospective, randomized, double-blind (pharmacotherapy), placebo-controlled, and comprehensive physiotherapy and nutritional intervention phase II clinical trial to determine the usefulness of nandrolone decanoate in a new indication (sarcopenia). Patients will be randomized 1:1 to receive nandrolone decanoate (50 mg intramuscular injection over four visits every 3 weeks) or placebo (1 ml volume equivalent to 50 mg intramuscular nandrolone decanoate dose) for 12 weeks (83-85 days ). Both groups will receive comprehensive physiotherapy and nutritional intervention. There will be 5 outpatient visits to the research center. The procedures and assessments performed as part of the study are listed in the study schedule. It is planned to include 168 patients in the study, which, assuming a 10% level of non-completion of the program, will result in the examination of 152 patients (76 in each arm). The study will cover people aged over 60 to 99 years of age with confirmed muscle weakness measured with a hand dynamometer (\< 27 kg for men and 16 kg for women) and with a decrease in: muscle mass of upper and lower limbs (ASMM) (7.0 kg/m2 height in men and 5.5 kg/m2 in women) or total muscle mass of the upper and lower extremities (\< 20 kg in men and \< 15 kg in women) by densitometry.

Conditions

Sarcopenia

Outcome Measures

Primary Outcomes (2)

• Change in physical fitness as assessed by the SPPB test score

  Change in physical fitness as assessed by the SPPB test score (4- meter gait speed test version) in points, at the 5th study visit relative to the test score performed at visit 1

  in the 12th week of the study

• Change in the 400-meter walk test score

  Change in the 400-meter walk test score in time units, at the 5th test visit, relative to the test score taken at visit 1

  in the 12th week of the study

Secondary Outcomes (5)

• lower limb muscle strength

  in the 6th and 12th week of the study

• Respiratory muscle strength

  in the 6th and 12th week of the study

• muscle mass

  in the 6th and 12th week of the study

• muscle mass of the upper and lower limbs

  in the 6th and 12th week of the study

• score of the Sarc-QoL quality of life questionnaire (validated Polish version)

  in the 6th and 12th week of the study

Study Arms (2)

Nandrolone

EXPERIMENTAL

Drug: Nandrolone Decanoate; Behavioral: Physiotherapy Intervention; Behavioral: Nutritional Intervention

Placebo

PLACEBO COMPARATOR

Behavioral: Physiotherapy Intervention; Behavioral: Nutritional Intervention; Drug: Placebo

Interventions

Nandrolone Decanoate DRUG

Patients will receive nandrolone decanoate (1 ml, 50 mg/ml intramuscularly given per visit) or placebo

Nandrolone

Physiotherapy Intervention BEHAVIORAL

The physiotherapeutic intervention includes the following components: 1. Strength training will include strength exercises 3 x a week x 30 min - load from 60% to 80% 1RM for individual muscle groups, - 10 repetitions of the exercise, - 1-3 series in 1 session (break between sessions 60 seconds). 2. Endurance training will include aerobic exercises (cycle ergometer, treadmill, general fitness exercises) 3 times a week x 30 minutes, load from 60% to 80% of maximum heart rate.

Nandrolone; Placebo

Nutritional Intervention BEHAVIORAL

An individual diet in terms of calorific value and the content of energy substrates - proteins, fats and carbohydrates, as well as other nutrients, in accordance with specific nutrition standards.

Nandrolone; Placebo

Placebo DRUG

Placebo

Placebo

Eligibility Criteria

• Age: 60 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• individuals aged 60 years or older through 99 years of age.
• Patients meeting the following criteria diagnosed with sarcopenia based on EWGSOP 2 criteria from 2019:
• weakness of muscle strength measured by hand dynamometer ( \< 27 kg for men and 16 kg for women) and
• reduction in densitometry:
• upper and lower limb muscle mass (ASMM)(below 7.0 kg/m2 height in men and 5.5 kg/m2 in women) or
• total muscle mass of the arms and legs in men less than 20 kg and less than 15 kg in women).

You may not qualify if:

• Mini-Mental State Examination (MMSE) score less than 24;
• malignant neoplasm, lymphoproliferative or myeloproliferative disorders requiring oncologic or palliative treatment and the period before: 5 years in the case of: malignant melanoma, leukemia, Hodgkin's disease, malignant lymphomas, kidney tumors, 12 months in the case of other malignant neoplasms after the completion of surgery, chemotherapy or radiotherapy;
• history of oncologic diagnosis of focal lesions in the prostate gland;
• acute and chronic inflammatory diseases of the gastrointestinal tract that present with malabsorption (celiac disease, ulcerative colitis, Crohn's disease, etc.);
• uncompensated hyper- or hypothyroidism;
• recent history of myocardial infarction or stroke (up to 4 weeks prior to study entry); history of thromboembolism (up to 6 months prior to study entry) or recurrent thromboembolism;
• poorly controlled hypertension;
• liver impairment (AST and/or ALT \> 3x normal: AST\> 111 U/l and ALT\> 123 U/l); 9 Acute kidney injury and/or chronic kidney disease (stage G4 and G5);
• \. nephrotic syndrome, acute or chronic glomerulonephritis; 11. advanced circulatory failure (NYHA stages III and IV); 12. Acute and chronic respiratory failure requiring oxygen therapy; 13. Amyotrophic lateral sclerosis, multiple sclerosis, myasthenia gravis, dystrophies, spinal muscular atrophy type IV, primary muscular disorders (ICD-10 G71), toxic-field myopathies, myopathies in the course of infectious and parasitic diseases. Epilepsy; 14. need for treatment during the study period:
• systemic corticosteroids for more than 3 weeks at a dose equivalent to greater than or equal to 5 mg prednisone;
• hormone replacement therapy,
• alpha reductase inhibitors,
• aromatase inhibitors,
• anti-estrogenic hormonal drugs with anabolic effects other than nandrolone decanoate,
• megestrol. 15. Lack of informed consent for participation in the study.

Sponsors & Collaborators

• National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland: lead
• Medical Research Agency, Poland: collaborator

Study Sites (1)

Centrum Wsparcia Badań Klinicznych

Warsaw, Masovian Voivodeship, 02-637, Poland

RECRUITING

MeSH Terms

Conditions

Sarcopenia

Interventions

Nandrolone Decanoate

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Intervention Hierarchy (Ancestors)

Nandrolone; Estrenes; Estranes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Testosterone Congeners; Gonadal Steroid Hormones; Gonadal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

• Tomasz Targowski, Prof. PhD, MD

  National Institute of Geriatrics, Rheumatology and Rehabilitation

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Iwona Jannasz

CONTACT

226709188; iwona.jannasz@spartanska.pl

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 28, 2023
• First Posted: August 7, 2023
• Study Start: August 10, 2023
• Primary Completion (Estimated): December 12, 2026
• Study Completion (Estimated): December 30, 2026
• Last Updated: April 8, 2026

Record last verified: 2025-05

Locations

PL (1)